JP2012522003A5 - - Google Patents

Download PDF

Info

Publication number
JP2012522003A5
JP2012522003A5 JP2012502264A JP2012502264A JP2012522003A5 JP 2012522003 A5 JP2012522003 A5 JP 2012522003A5 JP 2012502264 A JP2012502264 A JP 2012502264A JP 2012502264 A JP2012502264 A JP 2012502264A JP 2012522003 A5 JP2012522003 A5 JP 2012522003A5
Authority
JP
Japan
Prior art keywords
heteroaryl
group
cycloalkyl
aryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012502264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522003A (ja
JP5735482B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/028730 external-priority patent/WO2010111534A1/en
Publication of JP2012522003A publication Critical patent/JP2012522003A/ja
Publication of JP2012522003A5 publication Critical patent/JP2012522003A5/ja
Application granted granted Critical
Publication of JP5735482B2 publication Critical patent/JP5735482B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012502264A 2009-03-27 2010-03-25 縮合環のc型肝炎阻害剤 Expired - Fee Related JP5735482B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16434209P 2009-03-27 2009-03-27
US61/164,342 2009-03-27
US21488309P 2009-04-28 2009-04-28
US61/214,883 2009-04-28
PCT/US2010/028730 WO2010111534A1 (en) 2009-03-27 2010-03-25 Fused ring inhibitors of hepatitis c

Publications (3)

Publication Number Publication Date
JP2012522003A JP2012522003A (ja) 2012-09-20
JP2012522003A5 true JP2012522003A5 (cg-RX-API-DMAC7.html) 2013-05-09
JP5735482B2 JP5735482B2 (ja) 2015-06-17

Family

ID=42781523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012502264A Expired - Fee Related JP5735482B2 (ja) 2009-03-27 2010-03-25 縮合環のc型肝炎阻害剤

Country Status (19)

Country Link
US (1) US9150554B2 (cg-RX-API-DMAC7.html)
EP (1) EP2410843A4 (cg-RX-API-DMAC7.html)
JP (1) JP5735482B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110131312A (cg-RX-API-DMAC7.html)
CN (1) CN102427726B (cg-RX-API-DMAC7.html)
AR (1) AR076164A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010229795A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1012282A2 (cg-RX-API-DMAC7.html)
CA (1) CA2755658A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011002377A1 (cg-RX-API-DMAC7.html)
CO (1) CO6450600A2 (cg-RX-API-DMAC7.html)
EA (1) EA201190224A1 (cg-RX-API-DMAC7.html)
IL (1) IL215202A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011010132A (cg-RX-API-DMAC7.html)
PE (1) PE20120773A1 (cg-RX-API-DMAC7.html)
SG (1) SG174883A1 (cg-RX-API-DMAC7.html)
TW (1) TW201038560A (cg-RX-API-DMAC7.html)
WO (1) WO2010111534A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201107753B (cg-RX-API-DMAC7.html)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075380A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
MY169311A (en) 2009-03-27 2019-03-21 Merck Sharp & Dohme Inhibitors of hepatitis c virus replication
US20190127365A1 (en) 2017-11-01 2019-05-02 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
MX2011010132A (es) 2009-03-27 2011-10-14 Presidio Pharmaceuticals Inc Inhibidores de anillo fusionado de hepatitis c.
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
WO2010132538A1 (en) * 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
KR20180028070A (ko) 2009-05-13 2018-03-15 길리애드 파마셋 엘엘씨 항바이러스 화합물
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
CN103819459B (zh) 2009-06-11 2017-05-17 艾伯维巴哈马有限公司 抗病毒化合物
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2454254A2 (en) 2009-07-16 2012-05-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
EA025824B1 (ru) 2009-07-27 2017-02-28 Джилид Сайэнс, Инк. Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) * 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011075607A1 (en) * 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2012008658A (es) 2010-01-25 2012-12-05 Enanta Pharm Inc Inhibidores del virus de la hepatitis c.
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
EP2542074A4 (en) 2010-03-04 2014-05-14 Enanta Pharm Inc PHARMACEUTICAL COMBINATION ACTIVE AGENTS AS HCV REPLICATION INHIBITORS
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
WO2011127350A1 (en) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
WO2012003642A1 (en) * 2010-07-09 2012-01-12 Merck Sharp & Dohme Corp. Fused tricyclic compounds and use thereof for treating viral diseases
CA2805440A1 (en) * 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
JP2013540122A (ja) 2010-09-29 2013-10-31 メルク・シャープ・エンド・ドーム・コーポレイション 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
AU2011328980B2 (en) 2010-11-17 2015-07-30 Gilead Sciences, Inc. Antiviral compounds
RU2452735C1 (ru) 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012122716A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN103687489A (zh) 2011-05-18 2014-03-26 埃南塔制药公司 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法
NO3175985T3 (cg-RX-API-DMAC7.html) 2011-07-01 2018-04-28
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
CN102863428B (zh) 2011-07-09 2014-12-24 广东东阳光药业有限公司 作为丙型肝炎病毒抑制剂的螺环化合物
WO2013022810A1 (en) * 2011-08-08 2013-02-14 Glaxosmithkline Llc Chemical compounds
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
CA2840242C (en) 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
KR20210043734A (ko) 2011-11-16 2021-04-21 길리애드 파마셋 엘엘씨 항바이러스성 화합물로서의 축합된 이미다졸릴이미다졸
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ628515A (en) 2012-02-10 2016-06-24 Lupin Ltd Antiviral compounds with a dibenzooxaheterocycle moiety
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
CN103420991B (zh) * 2012-05-17 2017-07-07 乳源东阳光药业有限公司 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US9802949B2 (en) 2012-11-29 2017-10-31 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
TWI585082B (zh) 2012-11-29 2017-06-01 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的螺環化合物、藥物組合物及它們的用途
WO2014110687A1 (en) 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
EP3650013A1 (en) 2013-01-31 2020-05-13 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
RU2507201C1 (ru) 2013-02-07 2014-02-20 Александр Васильевич Иващенко Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN105530933B (zh) 2013-07-17 2018-12-11 百时美施贵宝公司 用于治疗hcv的包含联苯衍生物的组合产品
SI3038601T1 (sl) 2013-08-27 2020-07-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US9738629B2 (en) 2014-01-23 2017-08-22 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6746712B2 (ja) 2016-04-07 2020-08-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited タンパク質調節因子として有用な複素環式アミド
WO2017181383A1 (en) * 2016-04-21 2017-10-26 Merck Sharp & Dohme Corp. Hepatitis c virus inhibitors
CN118084940A (zh) 2018-02-13 2024-05-28 吉利德科学公司 Pd-1/pd-l1抑制剂
AU2019255750B2 (en) 2018-04-19 2021-10-21 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4341266A1 (en) 2021-05-21 2024-03-27 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors
US12497408B2 (en) 2021-05-21 2025-12-16 Gilead Sciences, Inc. Tetracyclic compounds and methods for the treatment of Zika virus infection
MA63501B1 (fr) 2021-06-14 2024-07-31 Scorpion Therapeutics, Inc. Dérivés d'urée pouvant être utilisés pour traiter le cancer

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127610C (cg-RX-API-DMAC7.html) 1965-06-23
CH532608A (de) * 1969-12-17 1973-01-15 Ciba Geigy Ag Verfahren zur Herstellung von Bis-aroxazolyl-Verbindungen
CH553807A (de) * 1970-12-23 1974-09-13 Sandoz Ag Verfahren zur herstellung von dibenzthiophendioxidderivaten.
US3808206A (en) 1971-06-29 1974-04-30 Richardson Merrell Inc Bis-basic ketones of phenoxathiins and antiviral compositions thereof
US4371690A (en) 1979-07-12 1983-02-01 E. I. Du Pont De Nemours And Company Heat-resistant rigid polymers from difunctional 9,10-dihydro-9,10-ethanoanthracenes
US5288914A (en) 1984-08-27 1994-02-22 The Dow Chemical Company Poly(arylcyclobutenes)
US5288924A (en) * 1992-09-18 1994-02-22 Mobil Oil Corporation Process for starting up an olefin hydration reactor
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
HUP0004421A3 (en) 1996-04-23 2002-10-28 Vertex Pharmaceuticals Inc Cam Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
EA001915B1 (ru) 1996-10-18 2001-10-22 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы серин-протеаз, в частности ns3 протеазы вируса гепатита c (hvc)
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
PT966465E (pt) 1997-03-14 2003-11-28 Vertex Pharma Inibidores do enzima imfdh
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
AU757072B2 (en) 1997-08-11 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptide analogues
ES2244204T3 (es) 1998-07-27 2005-12-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Derivados de dicetoacidos como inhibidores de polimerasas.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
IL141456A0 (en) 1998-08-21 2002-03-10 Viropharma Inc Rhodanine derivatives and pharmaceutical compositions containing the same
CA2343522A1 (en) 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
WO2000018231A1 (en) 1998-09-25 2000-04-06 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
AR029341A1 (es) 1999-03-19 2003-06-25 Vertex Pharma Inhibidores de la enzima impdh (inosina-5'-monofosfato dehidrogenasa)
US6242602B1 (en) 1999-03-29 2001-06-05 Gentex Corporation One pot synthesis of 5,10-dihydrophenazine compounds and 5,10-substituted dihydrophenazines
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
CA2449999C (en) 2001-06-11 2012-07-31 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
WO2002100851A2 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP2003212846A (ja) * 2001-06-26 2003-07-30 Japan Tobacco Inc 縮合環化合物及びc型肝炎治療剤
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
UA101465C2 (ru) * 2001-07-25 2013-04-10 Бёрингер Ингельхайм (Канада) Лтд. Использование индольного соединения для лечения или предупреждения инфицирования вирусом гепатита с
EP1440068A1 (en) 2001-11-02 2004-07-28 Glaxo Group Limited Acyl dihydro pyrrole derivatives as hcv inhibitors
EP1440069B1 (en) 2001-11-02 2007-08-15 Glaxo Group Limited 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
WO2003037894A1 (en) 2001-11-02 2003-05-08 Glaxo Group Limited 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
HRP20100048T1 (hr) 2004-01-30 2010-04-30 Medivir Ab Inhibitori hcv ns-3 serin proteaze
EP1804786A4 (en) 2004-09-29 2008-01-02 Cytovia Inc SUBSTITUTED N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS
WO2006050496A1 (en) * 2004-11-02 2006-05-11 E.I. Dupont De Nemours And Company Substituted anthracenes and electronic devices containing the substituted anthracenes
DE102005022020A1 (de) 2005-05-12 2006-11-23 Merckle Gmbh Dibenzocycloheptanverbindungen und pharmazeutische Mittel, welche diese Verbindungen enthalten
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7728027B2 (en) * 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en) * 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5266786B2 (ja) * 2008-02-20 2013-08-21 富士ゼロックス株式会社 新規なフェノチアジン化合物
WO2010096462A1 (en) * 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
MX2011010132A (es) 2009-03-27 2011-10-14 Presidio Pharmaceuticals Inc Inhibidores de anillo fusionado de hepatitis c.

Similar Documents

Publication Publication Date Title
JP2012522003A5 (cg-RX-API-DMAC7.html)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2012510523A5 (cg-RX-API-DMAC7.html)
JP2005511531A5 (cg-RX-API-DMAC7.html)
JP2016509047A5 (cg-RX-API-DMAC7.html)
RU2013108641A (ru) Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах
JP2013510886A5 (cg-RX-API-DMAC7.html)
JP2017537940A5 (cg-RX-API-DMAC7.html)
JP2017526675A5 (cg-RX-API-DMAC7.html)
RU2006134003A (ru) Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
JP2018522866A5 (cg-RX-API-DMAC7.html)
JP2010501478A5 (cg-RX-API-DMAC7.html)
JP2015532295A5 (cg-RX-API-DMAC7.html)
JP2016053042A5 (cg-RX-API-DMAC7.html)
RU2015107738A (ru) Ингибиторы hcv ns3 протеазы
KR20150114480A (ko) Hbv 감염에 대한 항바이러스 물질
JP2016510038A5 (cg-RX-API-DMAC7.html)
JP2005519932A5 (cg-RX-API-DMAC7.html)
JP2005535586A5 (cg-RX-API-DMAC7.html)
JP2005508967A5 (cg-RX-API-DMAC7.html)
JP2005508962A5 (cg-RX-API-DMAC7.html)
JP2006509842A5 (cg-RX-API-DMAC7.html)
JP2005505618A5 (cg-RX-API-DMAC7.html)
JP2013510178A5 (cg-RX-API-DMAC7.html)
JP2011503199A5 (cg-RX-API-DMAC7.html)